SCIEX OS Introduces New Software With OneOmics Suite and Molecule Profiler App

New introductions connect breakthrough technology to biological insight in a secure, cloud-based environment

SCIEX , a global leader in life science analytical technologies, continues to strengthen its software portfolio with new applications. OneOmics suite , now commercialized, supports big data, multi-omics research through the power of secure, collaborative cloud computing on SCIEX Cloud. The Molecule Profiler app extends beyond traditional drug metabolism software to add capabilities for the identification and quantification of biopharmaceutical metabolites and impurities, and provides a single solution to support the safety of life-saving therapies.

SCIEX OS is an entire LC-MS software ecosystem that enables scientists to easily get the most out of every sample. It is continually being updated to meet the evolving workflow needs of our customers, including support for the ZenoTOF 7600 system , the new accurate mass system from SCIEX. Systems powered by SCIEX OS have intuitive data acquisition, powerful data processing, and data integrity through traceable audit trails. Soon to be available in 9 languages, SCIEX OS helps scientists ensure completeness and consistency across all labs, instruments and workflows.

SCIEX Cloud and OneOmics suite

To advance the detection and treatment of disease, it is critical to understand how the thousands of mRNA transcripts, proteins, lipids and metabolites in the body are regulated and modified. The large-scale study of these molecules is the field of omics. OneOmics suite enables life science researchers to process large-scale proteomics and metabolomics data sets with ease, and up to 10x faster than desktop computing, reducing processing time from hours to minutes.

With SCIEX Cloud, data are securely stored in the cloud, allowing researchers to process their data from anywhere, anytime, and collaborate globally to integrate data from transcriptomics, proteomics and metabolomics. These increases in productivity will support breakthrough discoveries in the field of biomarker research.

To learn more about OneOmics suite and SCIEX Cloud, see here .

Molecule Profiler app

To bring life-saving small molecule and biopharmaceutical therapies to market safely, it is critical to understand how they are metabolized in the body. Molecule Profiler enables scientists to identify and quantify biotransformations and impurities across a wide range of molecular classes, including therapeutic oligonucleotides, small molecule drugs, peptide therapeutics and antibody-drug conjugates.

Combined with the superior sensitivity of the ZenoTOF 7600 system, it becomes easy to detect low-level metabolites and understand their in vivo metabolism, ensuring that these revolutionary therapies can be brought to market faster.

"Software is the vital connector between technology and insights, that will drive discovery. Our customers told us that the new horizon in disease research is multi-omics, and we listened. They told us that the new frontier of next-generation biologics is oligonucleotide-based therapies, and we listened. We are proud to introduce software that prioritizes user experience and diversity of need, thus enabling the vision of our customers."
-
Beth Hazell, Senior Director of Software at SCIEX.

To learn more about Molecule Profiler app, see here .

About SCIEX

SCIEX delivers solutions for the precision detection and quantification of molecules, empowering our customers to protect and advance the wellness and safety of all. We have led the field of mass spectrometry for 50 years. From the launch of the first ever commercially successful triple quadrupole in 1981, we have developed groundbreaking technologies and solutions that influence life-changing research and outcomes.

Today, as part of the Danaher (NYSE: DHR) family of global life science and technology innovators, we continue to pioneer robust solutions in mass spectrometry and capillary electrophoresis. Our customers are able to quickly respond to environmental hazards, better understand biomarkers relevant to disease, improve patient care in the clinic, bring relevant drugs to market faster and keep food healthier and safer.

That's why thousands of life science experts around the world choose SCIEX to get the answers they can trust to better inform critical decisions that positively impact lives.

For more information, visit sciex.com .

Let's connect: Twitter , LinkedIn , Facebook , and Instagram .

Advances in human wellness depend on the power of precise science.

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics . All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks ).

© 2021 DH Tech. Dev. Pte. Ltd. RUO-MKT-12-13461-A.

Lulu VanZandt
Manager, Brand, Public Relations and Social Media, SCIEX
lulu.vanzandt@sciex.com
+1 (508) 383-7163
M: +1 (508) 782-9484

News Provided by Business Wire via QuoteMedia

The Conversation (0)

Medtronic announces FDA approval of newest-generation Evolut TAVR system for treatment of symptomatic severe aortic stenosis

The Evolutâ„¢ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the Evolut™ FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The latest Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

U.S. Patent Office rejects Axonics' latest challenge to Medtronic patents

Medtronic moves for patent infringement litigation to resume

Medtronic (NYSE:MDT), the global leader in healthcare technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has affirmed the validity of claims in two of its patents in an ongoing patent infringement lawsuit filed by Medtronic against Axonics over sacral neuromodulation (SNM) technologies. Cumulatively, the PTAB has now upheld the validity of five of the Medtronic patents at issue in this lawsuit.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company"), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2023. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.

2023 Highlights

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Glen Eagle Resources Inc.

(TheNewswire)

Glen Eagle Resources Inc.

Glen Eagle Resources Inc. ( TSX VENTURE: GER) ("Glen Eagle" or the "Company")  announces that the court has homologated the judgement, ordering the Company to pay Gem Yield Bahamas Limited a compensation of $1,875,895 dollars including interest and $90,000 in penalty

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2023 financial results on Thursday, March 21, 2024 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date : Thursday, March 21, 2024

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
CardieX Limited

Funding Commitment Agreement Update

CARDIEX Limited (ASX:CDX) (CARDIEX, the Company) provides an update on the Funding Commitment Agreement (FCA) with C2 Ventures Pty Limited (C2V, owned by Directors Niall Cairns and Craig Cooper) as announced on 8 November 2023.

Keep reading...Show less

Latest Press Releases

Related News

×